Atrial FibrillationPIAFNCT05860894
Post Intensive Care Unit Atrial Fibrillation
A study testing Implantable ECG holter device (Biomonitor3, Biotronik) in people with Atrial Fibrillation and Critical Illness, run by Centre Hospitalier Universitaire de Besancon at 1 site in France.
Trial summary
Atrial fibrillation (AF) is a common heart rhythm disorder in the intensive care unit (ICU). It can be precipitated by multiple factors but it is unclear whether AF persists after discharge from the ICU, and long term. This study will investigate whether AF recurs up to one year after ICU discharge. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Atrial Fibrillation, Critical Illness
- What is being tested?
- Implantable ECG holter device (Biomonitor3, Biotronik)
- Type of treatment
- Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 150 participants
- Where
- 1 siteFrance
- Study dates
- 19 Sep 2023to 10 Apr 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age >18 years
- New onset atrial fibrillation diagnosed in the ICU (12 lead ECG or documented episode of atrial fibrillation lasting at least 30 seconds)
- Patient hospitalized in the ICU with at least one of the following two criteria:
- orotracheal intubation for mechanical ventilation
- AND/OR treatment with amines (vasopressors or inotropic agents)
- Written informed consent
- Patient affiliated to a social security regime (or beneficiary thereof)
Who cannot join
- Documented history of atrial fibrillation
- patients admitted to the ICU after cardiothoracic surgery
- Patients with life expectancy <12 months
- Patients under legal or judicial protection
- Patients with no social security coverage
- Patients within the exclusion period of another clinical trial
Trial locations and contacts
1 site in 1 country.
About this study
Atrial fibrillation (AF) is a common heart rhythm disorder in the intensive care unit (ICU). It can be precipitated by multiple factors but it is unclear whether AF persists after discharge from the ICU, and long term. This study will investigate whether AF recurs up to one year after ICU discharge.
Read the detailed description
Atrial fibrillation (AF) is the most common heart rhythm disorder encountered in the intensive care unit (ICU). It can be precipitated by multiple factors present in critically ill patients, such as tissue hypoxia, metabolic disorders etc. There is a paucity of data regarding the persistence of AF in these patients after discharge from the ICU, and in the longer term. Therefore, this study will investigate whether AF recurs up to one year after ICU discharge using an implantable ECG Holter device in adult patients discharged alive from the ICU, with documented new onset AF.
- Conditions
- Atrial Fibrillation, Critical Illness
- Being tested
- Implantable ECG holter device (Biomonitor3, Biotronik)
- Keywords
- intensive care unit, atrial fibrillation
- Medical subject headings
- Atrial Fibrillation, Critical Illness
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Implantable ECG holter device (Biomonitor3, Biotronik)Device
Subcutaneous implantation of ECG holder device to monitor ECG
| Study group | Role | What they receive |
|---|---|---|
| Implantable ECG holter device | Experimental | Adult patients with new onset atrial fibrillation occuring in the ICU will be implanted with an implantable ECG holter device (Biomonitor3, Biotronik) to monitor arrhythmia episodes up to 2 years after ICU discharge. Receives: Device: Implantable ECG holter device (Biomonitor3, Biotronik) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of recurrence of atrial fibrillation
Any episode of atrial fibrillation, atrial tachycardia or atrial flutter lasting at least 1 minute, as documented on the implantable device recordings
Measured: up to 1 year after ICU discharge
Secondary outcomes (4)
Burden of atrial fibrillation in absolute value
Burden of atrial fibrillation assessed as time (in days, hours and minutes), expressed as a absolute value
Measured: up to 2 years after ICU discharge
Burden of atrial fibrillation (percentage of time spent in atrial fibrillation)
Burden of atrial fibrillation assessed as time (in days, hours and minutes) expressed as a percentage time spent in atrial fibrillation
Measured: up to 2 years after ICU discharge
Rate of Stroke
Ischemic or hemorrhagei stroke documented by imaging, major bleeding (ISTH classification) or documented peripheral emboli
Measured: up to 2 years after ICU discharge
Number of participants with Change in treatment
Changes in treatment due to the discovery of atrial fibrillation
Measured: up to 2 years after ICU discharge
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 May 2023
- Study start19 Sep 2023
- Primary completion10 Apr 2025
- Study completion10 Apr 2025
Why it stopped: Insufficient recruitment
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Atrial FibrillationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 150 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire de Besancon
- Sponsor type
- University, hospital or other
- Collaborators
- Biotronik SE & Co. KG
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05860894
- Sponsor's protocol ID
- 2022-A01292-41
- Acronym
- PIAF
- Status last verified
- Sep 2025
- First submitted
- 27 Jan 2023
- Last updated
- 22 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Post Intensive Care Unit Atrial Fibrillation
- ClinicalTrials.gov ID
- NCT05860894
- Acronym / sponsor ID
- PIAF / 2022-A01292-41
- Conditions
- Atrial Fibrillation, Critical Illness
- Keywords
- intensive care unit, atrial fibrillation
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Insufficient recruitment
- Enrolment
- 150 participants (actual)
- Lead sponsor
- Centre Hospitalier Universitaire de BesanconUniversity, hospital or other
- Collaborators
- Biotronik SE & Co. KG
- Study start
- 19 Sep 2023 (actual)
- Primary completion
- 10 Apr 2025 (actual)
- Study completion
- 10 Apr 2025 (actual)
- First posted
- 16 May 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Atrial fibrillation (AF) is a common heart rhythm disorder in the intensive care unit (ICU). It can be precipitated by multiple factors but it is unclear whether AF persists after discharge from the ICU, and long term. This study will investigate whether AF recurs up to one year after ICU discharge.
Detailed description
Atrial fibrillation (AF) is the most common heart rhythm disorder encountered in the intensive care unit (ICU). It can be precipitated by multiple factors present in critically ill patients, such as tissue hypoxia, metabolic disorders etc. There is a paucity of data regarding the persistence of AF in these patients after discharge from the ICU, and in the longer term. Therefore, this study will investigate whether AF recurs up to one year after ICU discharge using an implantable ECG Holter device in adult patients discharged alive from the ICU, with documented new onset AF.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Implantable ECG holter device | Experimental | Device: Implantable ECG holter device (Biomonitor3, Biotronik)Adult patients with new onset atrial fibrillation occuring in the ICU will be implanted with an implantable ECG holter device (Biomonitor3, Biotronik) to monitor arrhythmia episodes up to 2 years after ICU discharge. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Age >18 years
- New onset atrial fibrillation diagnosed in the ICU (12 lead ECG or documented episode of atrial fibrillation lasting at least 30 seconds)
- Patient hospitalized in the ICU with at least one of the following two criteria:
- Written informed consent
- Patient affiliated to a social security regime (or beneficiary thereof)
Key exclusion criteria (6 listed)
- Documented history of atrial fibrillation
- patients admitted to the ICU after cardiothoracic surgery
- Patients with life expectancy <12 months
- Patients under legal or judicial protection
- Patients with no social security coverage
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Implantable ECG holter device (Biomonitor3, Biotronik)Subcutaneous implantation of ECG holder device to monitor ECG | Device | Implantable ECG holter device |
Primary outcome
Rate of recurrence of atrial fibrillation
Time frame: up to 1 year after ICU discharge
Any episode of atrial fibrillation, atrial tachycardia or atrial flutter lasting at least 1 minute, as documented on the implantable device recordings
4 secondary outcomes
Burden of atrial fibrillation in absolute value
Time frame: up to 2 years after ICU discharge
Burden of atrial fibrillation (percentage of time spent in atrial fibrillation)
Time frame: up to 2 years after ICU discharge
Rate of Stroke
Time frame: up to 2 years after ICU discharge
Number of participants with Change in treatment
Time frame: up to 2 years after ICU discharge
Results and safety
The study was stopped early (reason given: Insufficient recruitment). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Atrial Fibrillation
RecruitingObservational study
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
Chronic Lymphocytic Leukemia (CLL), Waldenstr(SqrRoot)(Delta)m s Macroglobulinemia
RecruitingObservational study
Mechanisms of Myocardial Injury and Ischemia in Patients With Rapid Atrial Fibrillation
Atrial Fibrillation (AF)
Recruiting
Posterior Mitral Isthmus Line With Vein of Marshall Ethanolisation Compared With Anterior Mitral Lines in Patients With Persistent Atrial Fibrillation
Persistent Atrial Fibrillation
Recruiting
PVI Alone vs PVI and Linear Ablation for Persistent Atrial Fibrillation (PROMPT AF II)
Persistent Atrial Fibrillation
RecruitingPhase 3
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
Atrial Fibrillation (AF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Implantable ECG holter device (Biomonitor3, Biotronik) in people with Atrial Fibrillation and Critical Illness, run by Centre Hospitalier Universitaire de Besancon at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 22 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Insufficient recruitment). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of recurrence of atrial fibrillation (time frame: up to 1 year after ICU discharge). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Oct 2026; AzTrials last refreshed its copy on 26 Oct 2026.